GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $3.85 Average Target Price from Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been assigned an average rating of “Hold” from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $3.9375.

Several equities research analysts have recently commented on GDRX shares. Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday. Wall Street Zen downgraded GoodRx from a “buy” rating to a “hold” rating in a research note on Sunday, January 25th. Citigroup reduced their price objective on GoodRx from $4.50 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Leerink Partners reissued an “outperform” rating and issued a $3.00 price objective on shares of GoodRx in a research note on Thursday, February 26th. Finally, Mizuho reduced their price objective on GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Friday, February 27th.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $2.92 on Wednesday. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81. The company has a market cap of $1.00 billion, a price-to-earnings ratio of 48.67, a P/E/G ratio of 2.02 and a beta of 1.54. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. The business has a fifty day simple moving average of $2.21 and a 200-day simple moving average of $2.58.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The business had revenue of $194.01 million during the quarter, compared to the consensus estimate of $185.40 million. During the same period in the prior year, the business posted $0.09 earnings per share. GoodRx’s revenue was down 4.4% compared to the same quarter last year. Sell-side analysts predict that GoodRx will post 0.15 EPS for the current year.

Institutional Investors Weigh In On GoodRx

Hedge funds have recently bought and sold shares of the business. Meridian Wealth Management LLC purchased a new stake in GoodRx in the 4th quarter worth about $29,000. SG Americas Securities LLC purchased a new stake in GoodRx in the 1st quarter worth about $29,000. Krilogy Financial LLC purchased a new stake in GoodRx in the 1st quarter worth about $33,000. Quarry LP purchased a new stake in GoodRx in the 3rd quarter worth about $33,000. Finally, MML Investors Services LLC purchased a new stake in GoodRx in the 4th quarter worth about $36,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.